Inhibition of influenza virus fusion by polyanionic proteins

Biochemical Pharmacology

Volumn 53, Issue 7, 1997, Pages 995-1003

  Schoen, Pieter ^a,b   Corver, Jeroen ^a   Meijer, Dirk K F ^a   Wilschut, Jan ^a   Swart, Pieter J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

antiviral agents; hemagglutinin; influenza virus; membrane fusion; polyanions; serum albumin

Indexed keywords

ANTIVIRUS AGENT; POLYANION; SERUM ALBUMIN;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA; INFLUENZA VIRUS; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL;

ERYTHROCYTE MEMBRANE; FLUORESCENCE; HEMAGGLUTININS, VIRAL; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOGLOBULINS; MEMBRANE FUSION; MEMBRANE LIPIDS; ORTHOMYXOVIRIDAE; SEMLIKI FOREST VIRUS; SERUM ALBUMIN;

EID: 0031009016     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00876-3     Document Type: Article

References (46)

1. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E and Meijer DKF, Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 39: 818-823, 1991.
2. Jansen RW, Schols D, Pauwels R, De Clercq E and Meijer DKF, Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 44: 1003-1007, 1993.
3. Swart PJ and Meijer DKF, Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Int Antivir News 2: 69-71, 1994.
4. Harmsen MC, Swart PJ, de Béthune MP, Pauwels R, De Clercq E, The TH and Meijer DKF, Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172: 380-388, 1995.
5. Kuipers ME, Huisman JG, Swart PJ, de Béthune MP, Pauwels R, Schuitemaker H, De Clercq E and Meijer DKF, Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120. J AIDS Hum Retrovirol 11: 419-429, 1996.
6. Swart PJ, Kuipers ME, Smit C, Pauwels R, de Béthune MP, De Clercq E, Meijer DKF and Huisman JG, Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus type 1 and 2 in vitro. AIDS Res Hum Retroviruses 12: 769-775, 1996.
7. Wiley DC and Skehel JJ, The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56: 365-394, 1987.
8. White JM, Viral and cellular membrane fusion proteins. Annu Rev Physiol 52: 675-697, 1990.
9. Webster RG, Bean WJ, Gorman OT, Chambers TM and Kawaoka Y, Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-179, 1992.
10. Wilson IA, Skehel JJ and Wiley DC, Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289: 366-373, 1981.
11. Wilschut J and Bron R, The influenza virus hemagglutinin: Membrane fusion activity in intact virions and reconstituted virosomes. In: Viral Fusion Mechanisms (Ed. Bentz J), pp. 133-160. CRC Press, Boca Raton, 1993.
12. Stegmann T, Membrane fusion: Anchors aweigh. Curr Biol 4: 551-554, 1994.
13. Hughson FM, Structural characterization of viral fusion proteins. Curr Biol 5: 265-274, 1995.
14. Stegmann T, Schoen P, Bron R, Wey J, Bartoldus I, Ortiz A, Nieva JL and Wilschut J, Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. Biochemistry 32: 11330-11337, 1993.
15. Stegmann T, Hoekstra D, Scherphof G and Wilschut J, Kinetics of pH-dependent fusion between influenza virus and liposomes. Biochemistry 24: 3107-3113, 1985.
16. Bron R, Wahlberg JM, Garoff H and Wilschut J, Membrane fusion of Semliki Forest virus in a model system: Correlation between fusion kinetics and structural changes in the envelope glycoprotein. EMBO J 12: 693-701, 1993.
17. Ames BN, Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 8: 115-118, 1966.
18. Bligh EG and Dyer WJ, A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
19. Böttcher CJF, van Gent CM and Pries C, A rapid and sensitive sub-micro phosphorus determination. Anal Chim Acta 24: 203-204, 1961.
20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
21. Habeeb AFSA, Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 14: 328-336, 1966.
22. Jansen RW, Molema G, Harms G, Kruijt JK, van Berkel TJC, Hardonk MJ and Meijer DKF, Formaldehyde treated albumin contains monomeric and polymeric forms that are differently cleared by endothelial and Kupffer cells of the liver: Evidence for scavenger receptor heterogeneity. Biochem Biophys Res Comm 180: 23-32, 1991.
23. Jansen RW, Molema G, Ching TL, Oosting R, Harms G, Moolenaar F, Hardonk MJ and Meijer DKF, Hepatic endocytosis of various types of mannose-treated albumins. What is important, sugar recognition, net charge, or the combination of these features. J Biol Chem 266: 3343-3348, 1991.
24. Stegmann T, Morselt HWM, Booy FP, van Breemen JFL, Scherphof G and Wilschut J, Functional reconstitution of influenza virus envelopes. EMBO J 6: 2651-2659, 1987.
25. Bron R, Ortiz A, Dijkstra J, Stegmann T and Wilschut J, Preparation, properties and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol 220: 313-331, 1993.
26. Steck TL and Kant JA, Preparation of impermeable ghosts and inside-out vesicles from human erythrocyte membranes. Methods Enzymol 31: 172-180, 1974.
27. Hope MJ, Bally MB, Webb G and Cullis PR, Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812: 55-65, 1985.
28. Chen Y, Rubin RJ and Szabo A, Fluorescence dequenching kinetics of single cell-cell fusion complexes. Biophys J 65: 325-333, 1993.
29. Stegmann T, Hoekstra D, Scherphof G and Wilschut J, Fusion activity of influenza virus. A comparison between biological and artificial target membrane vesicles. J Biol Chem 261: 10966-10969, 1986.
30. Wilschut J, Corver J, Nieva JL, Bron R, Moesby L, Reddy CK and Bittman R, Fusion of Semliki Forest virus with cholesterol-containing liposomes at low pH: A specific requirement for spingolipids. Mol Membr Biol 12: 143-149, 1995.
31. Stegmann T, White JM and Helenius A, Intermediates in influenza induced membrane fusion. EMBO J 9: 4231-4241, 1990.
32. Stegmann T, Delfino JM, Richards FM and Helenius A, The HA2 subunit of influenza hemagglutinin inserts into the target membrane prior to fusion. J Biol Chem 266: 18404-18410, 1991.
33. Lüscher-Mattli M and Glück R, Dextran sulfate inhibits the fusion of influenza virus with model membranes, and suppresses influenza virus replication in vivo. Antiviral Res 14: 39-50, 1990.
34. Krumbiegel M, Dimitrov DS, Puri A and Blumenthal R, Dextran sulfate inhibits fusion of influenza virus and cells expressing influenza hemagglutinin with red blood cells. Biochim Biophys Acta 1110: 158-164, 1992.
35. Herrmann A, Korte T, Arnold K and Hillebrecht B, The influence of dextran sulfate on influenza A virus fusion with erythrocyte membranes. Antiviral Res 19: 295-311, 1992.
36. Lüscher-Mattli M, Glück R, Kempf C and Zanoni-Grassi M, A comparative study of the effect of dextran sulfate on the fusion and the in vitro replication of influenza A and B, Semliki Forest, vesicular stomatitis, rabies, Sendai, and mumps virus. Arch Virol 130: 317-326, 1993.
37. Marsh M and Pelchen-Matthews A, Entry of animal viruses into cells. Rev Med Virol 3: 173-185, 1993.
38. Pass D and Kim PS, Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin. Curr Biol 5: 1377-1383, 1995.
39. Rabenstein M and Shin YK, A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation. Biochemistry 34: 13390-13397, 1995.
40. Bernstein HB, Tucker SP, Kar SR, McPherson SA, McPherson DT, Dubay JW, Lebowitz J, Compans RW and Hunter E, Oligomerization of the hydrophobic heptad repeat of gp41. J Virol 69: 2745-2750, 1995.
41. White JM, Membrane fusion. Science 258: 917-924, 1992.
42. Freed EO and Martin MA, The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Bio! Chem 270: 23883-23886, 1995.
43. Garoff H, Frischauf AM, Simons K, Lehrach H and Delius H, Nucleotide sequence of cDNA coding for Semliki Forest virus membrane glycoproteins. Nature 288: 236-241, 1980.
44. Kielian M, Membrane fusion and the alphavirus life cycle. Adv Virus Res 45: 113-151, 1995.
45. Lopalco L, Ciccomascolo F, Lanza P, Zoppetti G, Caramazza I, Leoni F, Beretta A and Siccardi AG, Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity. AIDS Res Hum Retroviruses 10: 787-793, 1994.
46. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM, Lorentsen KJ, Hendrix CW, Petty BG and Lietman PS, Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrobiol Agents Chemother 35: 2544-2550, 1991.